SCHEMBL19979243

SCHEMBL19979243

CC(C)C(=O)C1(F)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTT P42858 2/20 0.38
ATM Q13315 1/20 0.38
NR1H2 P55055 2/20 0.36
HPGD P15428 1/20 0.36
EPHX2 P34913 1/20 0.35
USP30 Q70CQ3 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DPP4 P27487 1/20 0.34
RECQL P46063 1/20 0.34
EPHX1 P07099 1/20 0.34
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12384327 0.82 USP2 (0.48) USP2SMN1; SMN2HTTATMNR1H2
SCHEMBL15114223 0.81 USP2 (0.42) USP2SMN1; SMN2HTTATMNR1H2
SCHEMBL23019549 0.81 CYP2C9 (0.39) USP2ALDH1A1MAPK1TSHR
SCHEMBL14917424 0.81 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL18420280 0.79 USP2 (0.43) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL23925508 0.79 USP2 (0.43) USP2SMN1; SMN2HTTATMNR1H2
SCHEMBL12445298 0.78 USP2 (0.48) USP2SMN1; SMN2HTTATMNR1H2
SCHEMBL21063592 0.78 USP2 (0.42) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL21098079 0.77 USP2 (0.47) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL34474707 0.77 USP2 (0.41) USP2SMN1; SMN2NR1H2HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11220517-B2 Spiro bicyclic inhibitors of menin-MLL interaction JANSSEN PHARMACEUTICA NV (BE) 2022-01-11 US disclosed
US-20190211036-A1 SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2019-07-11 US disclosed
WO-2018050686-A1 SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220517-B2 Spiro bicyclic inhibitors of menin-MLL interaction BMI1, MLLT1, MEN1 USP2 4758/4885SMN1; SMN2 1605/4885HTT 3331/4885
US-20190211036-A1 SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION BMI1, MLLT1, MEN1 USP2 4557/4885SMN1; SMN2 1839/4885HTT 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.